

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

SECTION 1. IDENTIFICATION

Product name : Temozolomide Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Acute toxicity (Oral)	: Category 4
Eye irritation	: Category 2A
Germ cell mutagenicity	: Category 2
Carcinogenicity	: Category 2
Reproductive toxicity	: Category 1B
Specific target organ toxicity - repeated exposure (Oral)	: Category 1 (Bone marrow, thymus gland, Lymph nodes, spleen)

Other hazards

Contact with dust can cause mechanical irritation or drying of the skin.

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H302 Harmful if swallowed.
H319 Causes serious eye irritation.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version 11.0 Revision Date: 04/14/2025 SDS Number: 25460-00026 Date of last issue: 12/19/2024
Date of first issue: 10/24/2014

H341 Suspected of causing genetic defects.
H351 Suspected of causing cancer.
H360FD May damage fertility. May damage the unborn child.
H372 Causes damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Temozolomide	85622-93-1*	>= 9 - <= 56	-
Stearic acid	57-11-4*	>= 1 - <= 5	TSC
(+)-Tartaric acid	87-69-4*	>= 1 - <= 5	TSC

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Harmful if swallowed. Causes serious eye irritation. Suspected of causing genetic defects. Suspected of causing cancer. May damage fertility. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Metal oxides
Specific extinguishing method	: Use extinguishing measures that are appropriate to local cir-

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

ods

cumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.
for fire-fighters Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m ³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m ³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
	15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
Dust, nuisance dust and particulates	10 mg/m ³ Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL
	5 mg/m ³ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version 11.0 Revision Date: 04/14/2025 SDS Number: 25460-00026 Date of last issue: 12/19/2024
Date of first issue: 10/24/2014

Stearic acid	57-11-4	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable. Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.
Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions,

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Skin and body protection	: mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Color	: off-white
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm ³
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 559.98 mg/kg
Method: Calculation method

Components:

Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg
LD50 (Rat): 315 mg/kg
LD50 (Mouse): 205 mg/kg

Stearic acid:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2 mg/l
Exposure time: 1 h
Test atmosphere: vapor
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

(+)-Tartaric acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Stearic acid:

Species : Rabbit
Method : Patch Test 24 Hrs.
Result : No skin irritation

(+)-Tartaric acid:

Species : Rabbit
Method : OECD Test Guideline 404

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

||Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Stearic acid:

Species	: Rabbit
Result	: No eye irritation

(+)-Tartaric acid:

Species	: Bovine cornea
Method	: OECD Test Guideline 437

||Result : Irreversible effects on the eye

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Temozolomide:

Test Type	: Maximization Test
Routes of exposure	: Dermal
Species	: Guinea pig
Result	: negative

Stearic acid:

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative
Remarks	: Based on data from similar materials

(+)-Tartaric acid:

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative

Germ cell mutagenicity

Suspected of causing genetic defects.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Components:

Temozolomide:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: positive Test Type: Chromosome aberration test in vitro Test system: Human lymphocytes Result: positive
Germ cell mutagenicity - Assessment	: Positive results from in vitro mammalian mutagenicity assays, chemical structure activity relationship to known germ cell mutagens

Stearic acid:

Genotoxicity in vitro	: Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials
-----------------------	--

(+)-Tartaric acid:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: positive
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Carcinogenicity

Suspected of causing cancer.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Components:

Temozolomide:

Species	: Rat
Application Route	: Oral
Exposure time	: 6 Months
	: 4 mg/kg body weight
Result	: positive
Target Organs	: Mammary gland

Carcinogenicity - Assessment	: Limited evidence of carcinogenicity in animal studies
------------------------------	---

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Temozolomide:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: LOAEL: 8.5 mg/kg body weight Result: positive
----------------------	--

Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Embryo-fetal toxicity.: LOAEL: 13 mg/kg body weight Result: positive, Malformations were observed.
------------------------------	---

Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
------------------------------------	--

Stearic acid:

Effects on fertility	: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
----------------------	--

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Effects on fetal development : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

(+)-Tartaric acid:

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Components:

Temozolomide:

Routes of exposure : Ingestion
Target Organs : Bone marrow, thymus gland, Lymph nodes, spleen
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Temozolomide:

Species : Rat, female
NOAEL : 4 mg/kg
LOAEL : 21 mg/kg
Application Route : Oral
Exposure time : 6 Months
Target Organs : thymus gland, Bone marrow, Reproductive organs, Lymph nodes

Species : Rat, male
NOAEL : 8.5 mg/kg
LOAEL : 34 mg/kg
Application Route : Oral
Exposure time : 6 Months
Target Organs : thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract, Lymph nodes

Species : Dog
NOAEL : 2.5 mg/kg
LOAEL : 6.3 mg/kg

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland

Stearic acid:

Species	: Rat
NOAEL	: 1,000 mg/kg
Application Route	: Ingestion
Exposure time	: 42 Days
Method	: OECD Test Guideline 422
Remarks	: Based on data from similar materials

(+)-Tartaric acid:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Temozolomide:

Ingestion	: Symptoms: Blood disorders, Nausea, Vomiting, Diarrhea, anorexia, Fatigue, hair loss
-----------	---

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Temozolomide:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Stearic acid:

Toxicity to fish : LL50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l
Exposure time: 48 h
Method: DIN 38412

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : NOELR (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOELR (Daphnia magna (Water flea)): > 0.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to microorganisms : EC10 (Pseudomonas putida): 883 mg/l
Exposure time: 18 h

(+)-Tartaric acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 93.313 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): 51.404

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

plants	mg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 3.125 mg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50: > 1,000 mg/l
	Exposure time: 3 h
	Method: OECD Test Guideline 209

Persistence and degradability

Components:

Temozolomide:

Biodegradability	: Result: rapidly degradable
	Biodegradation: 83 %
	Exposure time: 35 d
Stability in water	: Degradation half life (DT50): < 1 d

Stearic acid:

Biodegradability	: Result: Readily biodegradable.
	Biodegradation: 71 %
	Exposure time: 28 d
	Method: OECD Test Guideline 301B

(+)-Tartaric acid:

Biodegradability	: Result: Readily biodegradable.
	Biodegradation: 85 %
	Exposure time: 28 d
	Method: OECD Test Guideline 306

Bioaccumulative potential

Components:

Temozolomide:

Partition coefficient: n-octanol/water	: log Pow: 1.35
--	-----------------

Stearic acid:

Partition coefficient: n-octanol/water	: log Pow: 8.23
--	-----------------

(+)-Tartaric acid:

Partition coefficient: n-octanol/water	: log Pow: -1.91
--	------------------

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Combustible dust Acute toxicity (any route of exposure) Germ cell mutagenicity Carcinogenicity Reproductive toxicity
----------------------	---	--

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

Specific target organ toxicity (single or repeated exposure)
Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Lactose	63-42-3
Temozolomide	85622-93-1
Starch, carboxymethyl ether, sodium salt	9063-38-1
Stearic acid	57-11-4


The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
CAL PEL	: California permissible exposure limits for chemical contaminants (Title 8, Article 107)

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
CAL PEL / PEL	:	Permissible exposure limit
OSHA Z-3 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
--	---	---

Revision Date	:	04/14/2025
---------------	---	------------

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Temozolomide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/19/2024
11.0	04/14/2025	25460-00026	Date of first issue: 10/24/2014

SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8